NVO | tickerfilter.com

Fundamental analysis

48%

Profitability 64%

Dept financing 16%

Liquidity 52%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-21.30%

1 Month

-19.09%

3 Months

-31.29%

6 Months

-40.26%

1 Year

-17.24%

2 Year

27.23%

Key data

Stock price

$132.11

P/E Ratio

0.00

DAY RANGE

$82.87 - $132.11

EPS

$0.00

52 WEEK RANGE

$86.53 - $148.15

52 WEEK CHANGE

-$17.24

MARKET CAP

471.770 B

YIELD

1.04%

SHARES OUTSTANDING

3.390 B

DIVIDEND

$0.5126

EX-DIVIDEND DATE

08/16/2024

NEXT EARNINGS DATE

11/06/2024

BETA

0.90

PUBLIC FLOAT

AVERAGE 10 VOLUME

$11,933,044

AVERAGE 30 VOLUME

$7,389,766

Company detail

CEO: Lars F. Jørgensen
Region: US
Website: novonordisk.com
Employees: 54,400
IPO year: -

Issue type: American Depository Receipt (ADR’s)
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

Novo Nordisk A/S engages in the research, development, manufacture, and marketing of pharmaceutical products. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in areas of haemophilia, growth disorders, and hormone replacement therapy. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

NVO - NOVO NORDISK A S